Meta-analysis on radiofrequency ablation in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma

Abstract

To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) and TACE alone for hepatocellular carcinoma (HCC), Pubmed, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI) and Wanfang Datebases were searched for the randomized controlled trials (RCTs) and retrospective cohort studies from the establishment of the databases to January 2014. The bibliographies of the included studies were searched, too. After study selection, assessment, data collection and analysis were undertaken, we performed this meta-analysis by using the RevMan5.2 software. Seventeen studies involving 1116 patients met the inclusion criteria with 530 treated with RFA-plus-TACE and 586 with TACE alone. The results of meta-analysis showed that the combination of TACE and RFA was obviously associated with higher 1-, 2-, and 3-year overall survival rates (OR_1-year=3.98, 95% CI 2.87–5.51, P<0.00001; OR_2-year=3.03, 95% CI 2.10–4.38, P<0.00001; OR_3-year=7.02, 95% CI 4.14–11.92, P<0.00001) than TACE alone. The tumor complete necrosis rate in patients treated with TACE and RFA was higher than that of TACE alone (OR=13.86, 95% CI 8.04–23.89, P<0.00001). And there was a significant difference in local recurrence rate between two different kinds of treatment (OR=0.24, 95%CI 0.14–0.44, P<0.00001). Additionally, combination of TACE and RFA was associated with higher complete tumor necrosis rates than TACE mono-therapy in the treatment of HCC. However, RFA plus TACE was found to be associated with a lower local recurrence rate than TACE monotherapy. TACE-plus-RFA treatment was associated with a higher response rate (RR) than the TACE-alone treatment (OR=3.90, 95% CI=2.37–6.42, P<0.00001). TACE-plus-RFA treatment did not differ from the TACE-alone treatment in terms of stable disease (SD) rate (OR=0.38, 95% CI=0.11–1.26, P=0.11). Meta-analyses showed that the combination of RFA and TACE was associated with a significantly lower progressive disease (PD) rate (OR=0.15, 95% CI=0.05–0.43, P=0.0005). The rate of AFP reducing or returning to normal in serum in RFA plus TACE group was obviously lower than TACE alone group (OR=4.62, 95% CI 2.56–8.34, P<0.00001). The effect of TACE plus RFA for HCC is better than TACE mono-therapy. The combined therapy can elevate the patients’ overall survival rate, tumor necrosis rate and the rate of AFP reducing or returning to normal in serum and decrease local recurrence rate, PD rate compared with TACE alone.

Keywords

hepatocelluar carcinoma / transarterial chemoembolization / radiofrequency ablation / meta-analysis

References

[1] YangP, LiangM, ZhangY, et al. . Clinical Application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Ther, 2008, 25(8): 787-794 PMID: 18670743

[2] KirikoshiH, SaitoS, YonedaM, et al. . Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatol Res, 2009, 39(6): 553-562 PMID: 19527484

[3] MorimotoM, NumataK, KondoM, et al. . Radiofrequency ablation combinationed with transarterial chemoembolization for subcapsular hepatocellular carcinoma: A prospective cohort study. Eur J Radiol, 2013, 82(3): 497-503 PMID: 23068563

[4] WangYB, ChenMH, YanK, et al. . Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Quality Life Res, 2007, 16(3): 389-397

[5] ShibataT, IsodaH, HirokawaY, et al. . Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequecy ablation alone for treatment?. Radiology, 2009, 252(3): 905-913 PMID: 19567647

[6] DaiXD, WangY, ChengZ, et al. . Therapeutic effect of trans-arterial chemo-embolization in combination with radio-frequency ablation for the treatment of middle or advanced stage hepatocellular carcinoma. Fangshexue Shijian Zazhi (Chinese), 2010, 25(7): 799-801

[7] MalagariK, PomoniM, SpyridopoulosTN, et al. . Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol, 2011, 34(4): 774-785 PMID: 21184228

[8] MorimotoM, NumataK, KondouM, et al. . Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer, 2010, 116(23): 5452-5460 PMID: 20672352

[9] CaiZ, WanLX, WangWL, et al. . Clinical observation of the TACE combined with RFA treatment in malignant hepatic carcinoma. Zhongguo Shiyong Yiyao Zazhi (Chinese), 2013, 8(8): 1-3

[10] HuangYH, XuQ, ShenT, et al. . Clinical efficacy and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of advanced hepatocellular carcinoma. Hainan Yixue Zazhi (Chinese), 2013, 24(24): 3630-3632

[11] SongW, JiangSF, LongHY, et al. . Clinical application of transcatheter arterial chemoembolization combined with percutaneous radiofrequency in the treatment of large hepatic tumors. Chin J Curr Adv Gen Surg (Chinese), 2008, 11(3): 203-207

[12] ZhuangGY, LiJQ, ZhaoHF, et al. . Clinical effect comparison of radiofrequency ablation for liver cancer with different diameter. Chin J Curr Adv Gen Surg (Chinese), 2008, 11(5): 451-452

[13] ZhouJ, WangF. Clinical effects of transcatheter artery chemoembolization combined with radiofrequency ablation for treating hepatocellular carcinoma. Liaoning Yixue Zazhi (Chinese), 2007, 21(6): 369-371

[14] FangZX, ChenD, FangZH, et al. . Curative effects of hepatic arterial chemoembolization combined with radiofrequency ablation on larger hepatic carcinoma. Zhonghua Linchuang Yishi Zazhi (Chinese), 2012, 6(10): 2823-2825

[15] TanY, ZhangT, PengJJ, et al. . Curative effects of hepatic arterial chemoembolization combined with radiofrequency ablation on primary hepatic carcinoma in 76 cases. Xinan Guofang Yiyao Zazhi (Chinese), 2013, 23(8): 853-855

[16] ZhengL, GuoCY, LiHL, et al. . Trans-hepatic artery interventional thermo-chemotherapy and embolism combined with radiofrequency ablation in the treatment for hepatic carcinoma. Linchaung Fangshexue Zazhi (Chinese), 2013, 32(7): 1032-1035

[17] WuPH, ZhangFJ, ZhaoM, et al. . Combination of transcatheter arterial chemoembolization and CT-guided radiofrequency ablation in treating advanced hepatocellular carcinoma. Zhonghua Fangshexue Zazhi (Chinese), 2003, 37(10): 901-904

[18] DengLP, ZhangHW, DengXJ, et al. . The clinical application of hot lipiodol hepatic arterial chemoembolization combined with cool-tip radiofrequency ablation in treatment of hepatocellular carcinoma. Zhongnan Yixue Kexue Zazhi (Chinese), 2012, 40(3): 269-272

[19] HeCB, ZhuY, ZhangJJ, et al. . Clinical value of CT-guided radiofrequency ablation in combination with chemotherapy embolism of liver artery in the treatment of hepatocellular carcinoma. Weichuang Yixue Zazhi (Chinese), 2013, 8(3): 279-282

[20] TangSY, XieYB, JiangT, et al. . Clinical investigation of TACE, RFA and combined TACE and RFA in the therapy of PHC. Haerbin Yike Daxue Xuebao (Chinese), 2005, 39(2): 183-187

[21] Kang CB, Wang SL, Rui JA. Research of transcatheter artery chemoembolization combined with radiofrequency ablation for the treatment of large hepatocellular carcinoma. Linchuang Yiliao Zazhi (Chinese), 2007:137-140

[22] XiongJH, FanGR, ChenLQ, et al. . Therapeutic effect of transarterial chemo-embolization combined with radio frequency ablation for treatment of middle or advanced stage hepatocellular carcinoma in elderly. Chin J Curr Adv Gen Surg (Chinese), 2013, 16(5): 355-358

[23] ZhangZW. Primary liver cancer radiotherapy intervention analysis. Dangdai Yixue Zazhi (Chinese), 2011, 17(27): 70-71

[24] LiangMH. Chemical hepatic artery embolism combined radiofrequency ablation efficacy for the treatment of large hepatocellular carcinoma. Zhongguo Laonianxue Zazhi (Chinese), 2011, 31(15): 2862-2863

[25] BloomstonM, BinitieO, FraijiE, et al. . Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg, 2002, 68(9): 827-831 PMID: 12356160

[26] SunXJ, HeSL, ShenJ, et al. . Transarterial chemoembolization in combination with radio frequency thermal ablation in hepatocellular carcinoma: a systematic review and meta-analysis. Chin J Clin Med (Chinese), 2011, 18(6): 803-808

[27] Meza-JuncoJ, Montano-LozaAJ, LiuDM, et al. . Locoregional radiological treatment for hepatocellular carcinoma: Which, when and how?. Cancer Treat Rev, 2012, 38(1): 54-62 PMID: 21726960

[28] WangN, GuanQ, WangK, et al. . TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Med Oncol, 2011, 28(4): 1038-1043 PMID: 20632218

[29] LencioniR, CrocettiL. Radiofrequency Ablation of Liver Cancer. Tech Vasc Interv Radiol, 2007, 10(1): 38-46 PMID: 17980317

[30] IezziR, CesarioV, SicilianiL, et al. . Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE). Radiol Med, 2013, 118(4): 555-569 PMID: 23358819

[31] KimYS, LimHK, RhimH, et al. . Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: Analysis of prognostic factors. J Hepatol, 2013, 58(1): 89-97 PMID: 23023009

[32] McGahanJP, SacramentoMD. Radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg, 2004, 198(5): 853-854 PMID: 15110823

[33] KimJH, WonHJ, ShinYM, et al. . Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol, 2011, 18(6): 1624-1629 PMID: 21445671

[34] LuZ, WenF, GuoQ, et al. . Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol, 2013, 25(2): 187-194 PMID: 23134976

[35] LiZR, KangZ, QianJS, et al. . Radiofrequency ablation with or without transcather arterial chemoembolization for management of hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao (Chinese), 2007, 27(11): 1749-1751

[36] PengZW, ChenMS, LiangHH, et al. . A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol, 2010, 36(3): 257-263 PMID: 19643561

[37] GadaletaC, CatinoA, RanieriG, et al. . Single-step therapy-feasibility and Safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies. In Vivo, 2009, 23(5): 813-820 PMID: 19779117

[38] DuanX, ZhouG, ZhengC, et al. . Heat shock protein 70 expression and effect of combined transcatheter arterial embolization and radiofrequency ablation in the rabbit VX2 liver tumour model. Clin Radiol, 2014, 69(2): 186-193 PMID: 24199849